News & events

Press Releases

On the 28th March 2022, OncoArendi changed its name to Molecure

Dr. Zbigniew Zasłona joins OncoArendi Therapeutics as the new Director of the Biology Department. Dr Paweł Dobrzański, the current head of the Biology Department, will still be engaged in collaboration with OncoArendi as Senior Scientific Advisor on the company’s Scientific Advisory Board.

9 September 2020

Dr Timi Oshodi joined OncoArendi Therapeutics

3 July 2020

A new series of publications about the future prospects and development of Polish biotechnology sector was released by Technology Transfer and Entrepreneurship

13 May 2020

OncoArendi Therapeutics has completed a Phase Ib clinical trial with an innovative small molecule experimental drug – OATD-01. Further analyses of the data from the study will lead to the final report and advancing to phase II clinical trials in patients

20 April 2020

Drug Candidate OATD-01 may find use in treatment of pulmonary fibrosis in patients who have survived a new coronavirus infection (COVID-19)

24 March 2020

National Center for Research and Development (NCBR) funds OncoArendi Therapeutics’ new research platform of innovative anticancer drugs targeting deubiquitinase proteins.

31 January 2020

Events & Presentations

EFMC – International Symposium on Medicinal Chemistry – Ljubljana 02-06.09.2018

17 September 2018

ERS International Congress 2018 – Paris, France 15-19.09.2018

14 September 2018

54th International Conference on Medicinal Chemistry, Strasbourg, France – July 4-6, 2018.

17 July 2018

ATS 2018, 18 – 23 May, San Diego, USA

21 May 2018

ESMO Immuno Oncology Congress Geneva – December 7-10

1 December 2017

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 26 – 30, 2017

1 October 2017